
YKL-06-062
CAS No. 2172617-16-0
YKL-06-062( —— )
Catalog No. M33533 CAS No. 2172617-16-0
YKL-06-062 is a second-generation salt-inducible kinase (SIK) inhibitor that targets SIK1, SIK2, and SIK3, with IC50 values of 2.12 nM, 1.40 nM, and 2.86 nM, respectively.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 141 | Get Quote |
![]() ![]() |
5MG | 217 | Get Quote |
![]() ![]() |
10MG | 353 | Get Quote |
![]() ![]() |
25MG | 579 | Get Quote |
![]() ![]() |
50MG | 824 | Get Quote |
![]() ![]() |
100MG | 1098 | Get Quote |
![]() ![]() |
500MG | 2205 | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameYKL-06-062
-
NoteResearch use only, not for human use.
-
Brief DescriptionYKL-06-062 is a second-generation salt-inducible kinase (SIK) inhibitor that targets SIK1, SIK2, and SIK3, with IC50 values of 2.12 nM, 1.40 nM, and 2.86 nM, respectively.
-
DescriptionYKL-06-062 is a second-generation salt-inducible kinase (SIK) inhibitor with an IC50 of 2.12 nM/1.40 nM/2.86 nM for SIK1, SIK2 and SIK3, respectively.
-
In VitroYKL 06-062 (0.0004-16 μM; 3 hours) increases MITF mRNA expression in a dose-dependent manner.:RT-PCR Cell Line:Human melanocyte cells, UACC62 melanoma cells Concentration:0.0004 μM, 0.004 μM, 0.04 μM, 0.4 μM, 4 μM,8 μM,16 μM Incubation Time:3 hours Result:Unregulated MITF mRNA expression.
-
In Vivo——
-
Synonyms——
-
PathwayAutophagy
-
TargetSIK
-
RecptorSIK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2172617-16-0
-
Formula Weight525.69
-
Molecular FormulaC31H39N7O
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 25 mg/mL (47.56 mM; Ultrasonic )
-
SMILESCN1CCN(CC1)c1ccc(Nc2ncc3CN(C(=O)N(C4CCCCC4)c3n2)c2c(C)cccc2C)cc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Mujahid N, et al. A UV-Independent Topical Small-Molecule Approach for Melanin Production in Human Skin. Cell Rep. 2017 Jun 13;19(11):2177-2184.?
molnova catalog



related products
-
GLPG3970
GLPG3970 GLPG3970 is a novel orally available selective dual SIK2/SIK3 inhibitor.GLPG3970 has potential anti-inflammatory activity for the study of autoimmune diseases.
-
YKL-05-099
YKL-05-099 (YKL 05-099) is a novel potent, selective pan-SIK inhibitor with IC50 of 10, 40 and 30 nM for SIK1, 2 and 3, respectively.
-
MRT 199665
MRT 199665 is a potent salt-inducible kinases (SIKs) inhibitor with IC50 of 110, 12, 43 nM for SIK1,2,3 respectively.